Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| ANTX | An2 Therapeutics | $5.25 | $2.40 | 84.21% | 73.8K | $144M | $1.00$6.91 |
| HIMZ | Tidal Trust II - Defiance Daily Target 2x Long Hims ETF | $2.03 | $0.91 | 81.25% | 3.4M | - | $0.88$55.77 |
| DTCK | Davis Commodities | $2.49 | $1.06 | 74.13% | 59.4K | $68M | $1.32$137.80 |
| RLMD | Relmada Therapeutics | $7.17 | $2.72 | 61.12% | 41.5K | $526M | $0.24$7.41 |
| CAMP | Camp4 Therapeutics | $6.28 | $2.08 | 49.41% | 1.3K | $326M | $1.31$7.75 |
| XENE | Xenon Pharmaceuticals | $62.62 | $20.68 | 49.31% | 0 | $5.2B | $26.74$62.91 |
| HIMS | Hims & Hers Health | $22.16 | $6.42 | 40.79% | 1.2M | $5.1B | $13.74$70.43 |
| TURB | Turbo Energy | $5.05 | $1.27 | 33.60% | 86.3K | $56M | $0.57$20.45 |
| NERV | Minerva Neurosciences | $8.00 | $1.99 | 33.11% | 198 | $346M | $1.15$12.46 |
| EPSM | Epsium Enterprise | $2.30 | $0.56 | 32.18% | 78 | $30M | $1.04$155.00 |
| RNAC | Cartesian Therapeutics | $8.95 | $2.10 | 30.66% | 0 | $235M | $5.98$18.80 |
| ATRA | Atara Biotherapeutics | $6.74 | $1.57 | 30.37% | 0 | $48M | $3.92$19.15 |
| PIII | P3 Health Partners | $2.89 | $0.66 | 29.37% | 50 | $9.5M | $1.52$11.30 |
| PLYX | Polaryx Therapeutics | $3.52 | $0.78 | 28.47% | 1.8K | $167M | $2.20$48.91 |
| DDD | 3D Systems | $2.50 | $0.54 | 27.30% | 17 | $323M | $1.32$3.80 |
| QURE | uniQure | $17.99 | $3.72 | 26.07% | 40.3K | $1.1B | $7.76$71.50 |
Related Articles
Featured Article
Hims & Hers Health Shares Skyrocket on Novo Nordisk Deal, but Is the Stock Still a Buy?
Geoffrey Seiler|Mar 9, 2026
Hims & Hers stock traded more than 40% higher after the deal was announced.
Hims & Hers Stock Pops 40%: Everything You Need to Know
Travis Hoium|Mar 9, 2026
Hims & Hers shares are up over 40% on Monday after announcing a deal with Novo Nordisk.
Down 70% Over the Past Year, Can Hims & Hers Health Stock Bounce Back?
Geoffrey Seiler|Feb 27, 2026
The company is looking toward international markets to boost its growth.
Hims & Hers HUGE Acquisition News!
Travis Hoium|Feb 19, 2026
Hims & Hers is acquiring Eucalyptus and spreading its wings internationally.
Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast?
Bram Berkowitz|Feb 9, 2026
Hims & Hers could face difficulty in the future in selling copycat GLP-1 drugs.
Hims & Hers Takes On Novo Nordisk: What We Know Right Now
Travis Hoium|Feb 5, 2026
Hims & Hers fell on fear that Novo Nordisk would take action against the company's new oral GLP-1, but there's more to the story.
HUGE News: Hims & Hers Adds Cancer Testing to Labs Offering
Travis Hoium|Feb 4, 2026
Hims & Hers is moving beyond prescriptions to preventative testing.
Stocks to Love in 2026
Motley Fool Staff|Jan 11, 2026
Are you looking for investment opportunities in 2026?
Why Is Hims & Hers Stock Falling, and Should Investors Buy the Dip?
Parkev Tatevosian, CFA|Nov 26, 2025
The healthcare industry is ripe for disruption.
Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock?
Geoffrey Seiler|Nov 9, 2025
The company continues to have a strong growth outlook ahead.
